12:00 AM
Jul 26, 2010
 |  BioCentury  |  Product Development

Gold-plating Antigens

Midatech, Immunotope form Syntara to develop bacteria-like nanoparticle vaccines

Midatech Ltd. and partner Immunotope Inc. think they have a better way to raise an immune response against cancer antigens that will be attractive to investors as a stand-alone program. This is the concept behind Syntara LLC, a 50:50 joint venture announced last week between the nanotechnology and immunotherapy companies.

Syntara will focus on the development of therapeutic vaccines to treat chronic viral infections and certain cancers. Immunotope will contribute its cancer and viral antigens, while Midatech will provide the IP and know-how for its nanoparticle delivery technology.

According to Ramila Philip, president and CSO of Immunotope, the company has discovered and developed a large number of undisclosed cancer and viral antigens. "These antigens are sometimes a small peptide and they are not highly immunogenic by themselves. This is where Midatech's nanoparticles come in," she told BioCentury.

Midatech's technology uses gold nanoparticles as a scaffold to which antigens and other molecules necessary to target a particular cell can be...

Read the full 788 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >